Researchers at Brigham and Women’s Hospital have successfully used transcranial magnetic stimulation (TMS) to selectively target specific brain circuits for depression and anxiety, according to a study published in Nature Molecular Psychiatry. By shifting stimulation sites from the standard dorsolateral prefrontal cortex to the dorsomedial prefrontal cortex, clinicians can influence distinct symptom clusters, including irritability and insomnia, offering a new framework for precision psychiatry.
How Targeted TMS Differs From Traditional Depression Treatment
Standard TMS therapy for major depressive disorder relies on imprecise measurement. According to Brigham and Women’s Hospital (BWH) researchers, clinicians typically use scalp measurements to locate the dorsolateral prefrontal cortex. This method often leads to incidental variations in where the magnetic pulses actually strike the brain.
The new research suggests that these variations are not merely noise but data points. In previous trials, BWH psychiatrists observed that patients stimulated at the dorsolateral site showed improvements in classic depressive symptoms like sadness and suicidality. Conversely, those stimulated at the dorsomedial prefrontal cortex—an area previously considered experimental—reported relief from “anxiosomatic” symptoms, including irritability, insomnia, and sexual disinterest.
Up to 50% of people diagnosed with one psychiatric illness also meet the criteria for a second condition, a phenomenon known as comorbidity, according to Joseph Taylor, an assistant professor of psychiatry at Harvard Medical School.
Can TMS Be Used for Precision Psychiatric Care?
The recent trial randomized 36 patients with moderate to severe anxiety and depression to receive either standard or novel circuit stimulation. After 30 days of treatment, the relative change in symptoms differed significantly between the two groups, confirming that researchers could intentionally drive symptom-specific results.
Joseph Taylor, lead author of the study, notes that this approach represents a shift toward precision medicine. Rather than applying a one-size-fits-all protocol, clinicians may soon be able to match specific brain circuits to a patient’s unique symptom profile. This is particularly relevant because, as Samantha Baldi, an HMS visiting fellow in psychiatry, notes, these circuits were identified in a data-driven manner without relying on pre-existing assumptions about how brain regions function.
Why Does Targeted Stimulation Work?
Despite the positive clinical outcomes, the mechanism behind why these circuits improve specific symptoms remains unclear. According to Baldi, the study found no evidence that larger changes in brain circuit connectivity directly correlated to larger improvements in patient symptoms.
While the treatment successfully reduced anxiety and depression, the lack of a clear correlation between neural connectivity and clinical relief suggests that current imaging tools, like functional magnetic resonance imaging (fMRI), are still evolving. Taylor acknowledges that the field has limited tools for understanding these biological changes, but emphasizes that the ability to use fMRI for treatment planning is a significant step forward for the future of brain stimulation.
Pro Tips for Understanding TMS Technology
- Consistency is key: Most TMS clinical trials, including this one, require a regimen of 30 daily treatments to observe measurable shifts in mood and anxiety.
- Consult your specialist: TMS is generally reserved for patients who have not responded to traditional medication or psychotherapy.
- Look for data-driven centers: Ask your provider if they utilize fMRI-guided targeting, which is increasingly replacing manual scalp measurements in research settings.
Frequently Asked Questions
- Is TMS an invasive procedure?
- No. TMS uses noninvasive magnetic pulses to stimulate neurons and does not require surgery or anesthesia.
- What symptoms does targeted TMS treat?
- Current research indicates that targeting the dorsolateral prefrontal cortex helps with sadness and suicidality, while the dorsomedial prefrontal cortex may target irritability, insomnia, and anxiety.
- Are these findings ready for general practice?
- Researchers urge caution due to the small sample size of the recent study. While promising, the findings require larger trials before becoming standard clinical practice.
Are you interested in the intersection of neuroscience and mental health? Subscribe to our newsletter for the latest updates on precision psychiatry, or explore our archive of articles on evidence-based mental health treatments.
